Abou-Taleb, A., Kandeel, W., El-Shaer, A., Noah, K. (2021). Focused low intensity shock wave therapy for management of benign prostatic hyperplasia: A Preliminary study. Benha Journal of Applied Sciences, 6(5), 293-295. doi: 10.21608/bjas.2021.205414
A.A. Abou-Taleb; W.S.Kandeel Kandeel; A.A. El-Shaer; K.M Noah. "Focused low intensity shock wave therapy for management of benign prostatic hyperplasia: A Preliminary study". Benha Journal of Applied Sciences, 6, 5, 2021, 293-295. doi: 10.21608/bjas.2021.205414
Abou-Taleb, A., Kandeel, W., El-Shaer, A., Noah, K. (2021). 'Focused low intensity shock wave therapy for management of benign prostatic hyperplasia: A Preliminary study', Benha Journal of Applied Sciences, 6(5), pp. 293-295. doi: 10.21608/bjas.2021.205414
Abou-Taleb, A., Kandeel, W., El-Shaer, A., Noah, K. Focused low intensity shock wave therapy for management of benign prostatic hyperplasia: A Preliminary study. Benha Journal of Applied Sciences, 2021; 6(5): 293-295. doi: 10.21608/bjas.2021.205414
Focused low intensity shock wave therapy for management of benign prostatic hyperplasia: A Preliminary study
Urology, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
Abstract
Objective: assess the effectiveness of shock waves in bph management by patients who do not react to medical treatment Method and patients: This research is a prospective, non-randomized single-arm study at Benha University Hospital's Urology Department. This comprised (32) individuals with BPH, with or without at least 6 months of poor response to pharmacological treatment by one or more α-blockers, poor surgical candidates for co-morbidities or not interested in surgery. All patients underwent six LISWT sessions once a week, and all patients were assessed by changes in IPSS, QMAX, IIEF5, and PVRU at 3rd and 6th, and 3 months after treatment completion Results: substantial improvement was seen in the maximal flow rate from9±1.50ml/sec before to sessions beginning to 13.9±1.2ml/sec, and also in PVR from 79.34±56.87ml to 55.43±35.65ml during the sixth week of follow-up. The IPSS also improved substantially from 28±4.5 to 20.34±5 at the 6th week of follow-up. Conclusion:LISWT is safe to use for BPH treatment particularly in non-respondent medical therapy without severe side effects based on its antispasmodic characteristics.